POVETACICEPT

UNII:	EN2U82XV65
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	POVETACICEPT
GSRS Full Record:	EN2U82XV65 i

2490217-42-8
68-110-Tumor necrosis factor receptor superfamily protein TNFRSF13B [77-glutamic acid,78-tyrosine,102-aspartic acid] (human) fusion with peptide linker (GSGGGGS) fusion with immunoglobulin G1 [5-serine,19-alanine,20-glutamic acid,22-alanine,de-C-terminal-lysine] (human γ1-chain C-region C-terminal fragment), dimer
ALPN-303
ALPN-303 (DUAL BAFF/APRIL Fc Fusion Antagonist)
POVETACICEPT [USAN]
Povetacicept
Povetacicept [WHO-DD]
human TACI (transmembrane activator and CAML interactor, tumor necrosis factor receptor superfamily member 13B, TNFRSF13B, CD267) receptor domain 68-110 fragment (K77>E10, F78>Y11, Y102>D35)-mutant (1-43), fused via a GSG4S peptide linker (44-50) with 232 C-terminal residues of a mutated human immunoglobulin G1 gamma1 heavy chain (51-281) [Homo sapiens IGHG1*01, hinge C55>S (51-65), CH2 L69>A, L70>E, G72>A (66-175), CH3 (176-280), CHS K282>del (281)], (61-61':64-64')-bisdisulfide dimer, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 GS-, glycoform alfa
povetacicept [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

POVETACICEPT

Synonyms and Mappings

Resources